Comparative evaluation of the potential impact of rotavirus versus hpv vaccination in GAVI-eligible countries: A preliminary analysis focused on the relative disease burden

BMC Infectious Diseases

Volumn 11, Issue , 2011, Pages

  Kim, Sun Young ^a,b   Sweet, Steven ^a   Chang, Joshua ^a   Goldie, Sue J ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ROTAVIRUS VACCINE; WART VIRUS VACCINE;

ADOLESCENT; AGE; ARGENTINA; ARTICLE; BRAZIL; CANCER INCIDENCE; CANCER MORTALITY; CAUSAL ATTRIBUTION; CAUSE OF DEATH; CHILD; CHILD HOSPITALIZATION; CHILE; COHORT ANALYSIS; COLOMBIA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COSTA RICA; DRUG COST; FEMALE; GENDER; HUMAN; INDIA; INFANT; INFANT MORTALITY; KENYA; MALE; MEXICO; MOZAMBIQUE; NIGERIA; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PERU; ROTAVIRUS INFECTION; TANZANIA; UGANDA; UTERINE CERVIX CANCER; VACCINATION; VIET NAM; ZIMBABWE; ADULT; AFRICA; ASIA; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FINANCIAL MANAGEMENT; HEALTH CARE QUALITY; INTERNATIONAL COOPERATION; METHODOLOGY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AFRICA; ASIA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; FEMALE; FINANCIAL SUPPORT; HUMANS; INFANT; INTERNATIONAL AGENCIES; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROGRAM EVALUATION; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 79959215503     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-11-174     Document Type: Article

References (82)

1. Cost effectiveness of rotavirus vaccines and other interventions for diarrhoeal diseases: meeting report 2006. Wkly Epidemiol Rec 2006, 81(37):350-3.
2. WHO Vaccine introduction guidelines: adding a vaccine to a national immunization programme: decision and implementation. 2005, Geneva, Switzerland: WHO, Report No.:WHO/IVB/05.18, WHO.
3. Beutels P, Van Doorslaer E, Van Damme P, Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2003, 2:649-660. 10.1586/14760584.2.5.649, 14711326.
4. Goldie SJ, Goldhaber-Fiebert JD, Garnett GP. Chapter 18: Public health policy for cervical cancer prevention: The role of decision science, economic evaluation, and mathematical modeling. Vaccine 2006, 24(Suppl 3):S155-63.
5. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic evaluation: an unavoidable fact of life. Health Econ 1997, 6(3):217-27. 10.1002/(SICI)1099-1050(199705)6:3<217::AID-HEC267>3.0.CO;2-W, 9226140.
6. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 2008, 26:4080-93. 10.1016/j.vaccine.2008.04.053, 18550229.
7. Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis 2009, 200(Suppl 1):S28-38.
8. Rheingans RD, Antil L, Dreibelbis R, et al. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries. Journal of Infectious Diseases 2009, 200:S16-27. 10.1086/605026, 19817595.
9. Sinha A, Levine O, Knoll M, et al. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 2007, 369:389-96. 10.1016/S0140-6736(07)60195-0, 17276779.
10. Lydon P, Beyai PL, Chaudhri I, et al. Government financing for health and specific national budget lines: the case of vaccines and immunization. Vaccine 2008, 26:6727-34. 10.1016/j.vaccine.2008.06.090, 18625279.
11. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrants a different approach?. Lancet 2007, 8:727-33.
12. Jehu-Appiah C, Baltussen R, Acquah C, et al. Balancing equity and efficiency in health priorities in Ghana: the use of multicriteria decision analysis. Value in Health 2008, 11:1081-87. 10.1111/j.1524-4733.2008.00392.x, 19602214.
13. Baltussen R, Niessen L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Effectiveness and Resource Allocation 2006, 4:14. 10.1186/1478-7547-4-14, 1560167, 16923181.
14. Musgrove P, Fox-Rushby J. Chapter 15 Cost-effectiveness analysis for priority setting. Disease Control Priority Project 2.
15. Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O'Shea MKH, et al. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25:6257-70. 10.1016/j.vaccine.2007.05.058, 17606315.
16. Kim SY, Goldie SJ, Salomon JA. Cost-effectiveness of rotavirus vaccination in Vietnam. BMC Public Health 2009, 9:29. 10.1186/1471-2458-9-29, 2663769, 19159483.
17. Kim SY, Sweet S, Slichter D, Goldie SJ. Health and economics outcomes of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010, 10:253. 10.1186/1471-2458-10-253, 2893091, 20470426.
18. Goldie SJ, Diaz M, Constenla D, Alvis N, Andrus JK, Kim SY. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine 2008, 26(S11):L59-72.
19. Goldie SJ, Diaz M, Kim SY, Levin CE, Minh HV, Kim JJ. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008, 26(S12):M17-29.
20. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003, 81(3):197-204. 2572419, 12764516.
21. Parashar UD, Hummelman EG, Bresee JS, Miller MA, Glass RI. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9(5):565-72. 2972763, 12737740.
22. Gentsch JR, Woods PA, Ramachandran M, et al. Review of G and P typing results from a global collection of rotavirus strains: implications for vaccine development. J Infect Dis 1996, 174(Suppl 1):S30-S36.
23. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 2005, 15:29-56. 10.1002/rmv.448, 15484186.
24. WHO Meeting of the immunization Strategic Advisory Group of Experts, April 2009 - conclusions and recommendations. Weekly Epidemiological Record 2009, 84(23):220-236. WHO.
25. IARC Globocan 2008: cancer fact sheet. 2010, [accessed on October 23, 2010], IARC., http://globocan.iarc.fr/factsheets/cancers/cervix.asp
26. World Health Organization (WHO) Projections of mortality and burden of disease. [accessed on October 23, 2010], World Health Organization (WHO)., http://www.who.int/healthinfo/global_burden_disease/en/index.html
27. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1. HPV in the etiology of human cancer. Vaccine 2006, 24(Suppl 3):S1-10.
28. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-32. 10.1002/ijc.22527, 17405118.
29. WHO Prequalified Vaccines. WHO., http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html
30. GAVI Alliance GAVI Alliance Board Meeting October 2008. Doc #6 - Vaccine Investment Strategy, GAVI Alliance., http://www.who.int/immunization/sage/Vaccine_investment_strategy_implementation.pdf
31. Kim JJ, Kuntz KM, Stout NK, Mahmud S, Villa LL, Franco EL, et al. Multi-parameter calibration of a natural history model of cervical cancer. Am J Epidemiol 2007, 166:137-50. 10.1093/aje/kwm086, 17526866.
32. Kim JJ, Andres-Beck B, Goldie SJ. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br J Cancer 2007, 97(9):1322-8. 10.1038/sj.bjc.6604023, 2360471, 17923869.
33. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer 2008, 99(2):230-8. 10.1038/sj.bjc.6604462, 2480962, 18612311.
34. Kim JJ, Kobus KE, Diaz M, O'Shea M, Van Minh H, Goldie SJ. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 2008, 26(32):4015-24. 10.1016/j.vaccine.2008.05.038, 18602731.
35. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359(8):821-32. 10.1056/NEJMsa0707052, 3080183, 18716299.
36. Kim JJ, Goldie SJ. Cost-effectiveness analysis of including boys in a human papillomavirus (HPV) vaccination programme in the United States. BMJ 2009, 339:b3884. 10.1136/bmj.b3884, 2759438, 19815582.
37. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008, 26(3):191-215. 10.2165/00019053-200826030-00004, 18282015.
38. United Nations, Department of Economic and Social Affairs, Population Division World Population Prospects: The 2006 Revision. 2007, United Nations publication, Sales No. E.07.XIII.7, CD-ROM Edition - Extended Dataset in Excel and ASCII formats, United Nations, Department of Economic and Social Affairs, Population Division.
39. World Health Organization (WHO) Life tables for WHO member states. 2006, [accessed on January 29, 2008], World Health Organization (WHO)., http://apps.who.int/whosis/database/life/life_tables/life_tables.cfm?path=whosis
40. WHO Estimated rotavirus deaths for children under 5 years of age: 2004. WHO., http://www.who.int/immunization_monitoring/burden/rotavirus_estimates/en/index.html
41. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN2002. Cancer incidence, mortality and prevalence worldwide 2004, France: IARC Press, IARC Cancer BaseNo. 5 Version 2.0. Lyon.
42. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer incidence in five continents. 2005, I-VIII. IARC CancerBase No. 7. Lyon.
43. Parkin DM, Ferlay J, Hamdi-Che'rif M, Sitas F, Thomas JO, Wabinga H, Whelan SL, . (Eds.) Cancer in Africa: epidemiology and prevention. 2003, IARC Scientific Publications No. 153. Lyon: IARC, (Eds.).
44. Tan-Torres Edejer T, Baltussen R, Adam T, et al. (Eds.) Making choices in health: WHO guide to cost-effectiveness analysis. 2003, Geneva: World Health Organization, (Eds.).
45. Dey SK, Hayakawa Y, Rahman M, Islam R, Mizuguchi M, Okitsu S, Ushijima H. G2 strain of rotavirus among infants and children, Bangladesh. Emerg Infect Dis 2009, 15(1):91-4. 10.3201/eid1501.080883, 2660707, 19116061.
46. Steele AD, Ivanoff B. Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. Vaccine 2003, 21:361-7. 10.1016/S0264-410X(02)00616-3, 12531633.
47. Silva PA, Stark K, Mockenhaupt FP, Reither K, Weitzel T, Ignatius R, et al. Molecular characterization of enteric viral agents from children in northern region of Ghana. J Med Virol 2008, 80(10):1790-8. 10.1002/jmv.21231, 18712819.
48. Nielsen NM, Eugen-Olsen J, Aaby P, Molbak K, Rodrigues A, Fischer TK. Characterisation of rotavirus strains among hospitalized and non-hospitalised children in Guinea-Bissau, 2002: A high frequency of mixed infections with serotype G8. J Clin Virol 2005, 34(1):13-21. 10.1016/j.jcv.2004.12.017, 16087119.
49. Samajdar S, Ghosh S, Chawla-Sarkar M, Mitra U, Dutta P, Kobayashi N, et al. Increase in prevalence of human group A rotavirus G9 strains as an important VP7 genotype among children in eastern India. J Clin Virol 2008, 43(3):334-9. 10.1016/j.jcv.2008.07.007, 18755625.
50. Banerjee I, Ramani S, Primrose B, Moses P, Iturriza-Gomara M, Gray JJ, et al. Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol 2006, 44(7):2468-74. 10.1128/JCM.01882-05, 1489461, 16825366.
51. Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M, et al. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis 2005, 192(Suppl 1):S146-59.
52. Uchida R, Pandey BD, Sherchand JB, Ahmed K, Yokoo M, Nakagomi T, et al. Molecular epidemiology of rotavirus diarrhea among children and adults in Nepal: detection of G12 strains with P[6] or P[8] and a G11P[25] strain. J Clin Microbiol 2006, 44(10):3499-505. 10.1128/JCM.01089-06, 1594765, 17021073.
53. Espinoza F, Bucardo F, Paniagua M, Svensson L, Hallander HO, Bondeson K. Shifts of rotavirus g and p types in Nicaragua--2001-2003. Pediatr Infect Dis J 2006, 25(11):1078-80. 10.1097/01.inf.0000242739.44424.0e, 17072136.
54. Moyo SJ, Gro N, Kirsti V, Matee MI, Kitundu J, Maselle SY, et al. Prevalence of enteropathogenic viruses and molecular characterization of group A rotavirus among children with diarrhea in Dar es Salaam Tanzania. BMC Public Health 2007, 7:359. 10.1186/1471-2458-7-359, 2235852, 18162127.
55. Murray CJL, Lopez AD. Estimating causes of death: new methods and global and regional applications for 1990. The global burden of disease, vol. 1 of Global burden of disease and injury series 1996, 117-200. Cambridge, MA: Harvard University Press, Murray CJL, Lopez AD.
56. World Health Organization (WHO) Macroeconomics and Health Investing in Health for Economic Development: Report of the Commission on Macroeconomics and Health. 2001, Geneva: World Health Organization, World Health Organization (WHO).
57. Pitzer VE, Viboud C, Simonsen L, et al. Demographic Variability, Vaccination, and the Spatiotemporal Dynamics of Rotavirus Epidemics. Science 2009, 35:290-294.
58. de Blasio BF, Kasymbekova K, Flem E. Dynamic model of rotavirus transmission and the impact of rotavirus vaccination in Kyrgyzstan. Vaccine 2010, 28:7923-7932. 10.1016/j.vaccine.2010.09.070, 20933563.
59. Shim E, Galvani AP. Impact of transmission dynamics on the cost effectiveness of rotavirus vaccination. Vaccine 2009, 27:4025-30. 10.1016/j.vaccine.2009.04.030, 19389452.
60. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 2006, 24(Suppl 3):S178-86.
61. Kim JJ, Brisson M, Edmunds WJ, Goldie SJ. Modeling cervical cancer prevention in developed countries. Vaccine 2008, 26(11):K76-K86. 2769256, 18847560.
62. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006, 28:88-100. 10.1093/epirev/mxj006, 16740585.
63. Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau N. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009, 9:401. 10.1186/1471-2458-9-401, 2777872, 19878578.
64. Initiative for Vaccine, Research of WHO Department of Immunization, Vaccines and Biologicals of WHO WHO Guide for Standardization of Economic Evaluations of Immunization Programmes 2008. WHO/IVB/08.14, Initiative for Vaccine, Research of WHO Department of Immunization, Vaccines and Biologicals of WHO.
65. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, et al. Human Rotavirus Vaccine Study Group: Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22. 10.1056/NEJMoa052434, 16394298.
66. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl 10):K1-16.
67. Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl 10):K53-61. 2631230, 18847557.
68. Cuschieri K. Should boys receive the human papillomavirus vaccine? No. BMJ 2009, 339:b4921. 10.1136/bmj.b4921, 19969601.
69. Hibbitts S. Should boys receive the human papillomavirus vaccine? Yes. BMJ 2009, 339:b4928. 10.1136/bmj.b4928, 19969602.
70. Kim JJ. Vaccine policy analyses can benefit from natural history studies of human papillomavirus in men. J Infect Dis 2007, 196(8):1117-9. 10.1086/521199, 17955427.
71. Andrus JK, Sherris J, Fitzsimmons JW, Kane MA, Aguado MT. Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement. Vaccine 2008, 26(Suppl 10):K87-92.
72. Andrus JK, Lewis MJ, Goldie SJ, García PJ, Winkler JL, Ruiz-Matus C, de Quadros CA. Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean. Vaccine 2008, 26(Suppl 11):L80-7.
73. WHO A new approach to planning for immunization - WHO-UNICEF guidelines for developing a comprehensive multi-year plans (cMYP). WHO., http://www.who.int/immunization_financing/tools/cmyp/en/
74. PATH Shaping strategies to introduce HPV vaccines: formative research results from India, Peru, Uganda, and Vietnam. PATH., http://www.rho.org/formative-res-reports.htm
75. Burns JE, Mitrovich RC, Jauregui B, Matus CR, Andrus JK. Descriptive analysis of immunization policy decision making in the Americas. Rev Panam Salud Publica 2009, 26(5):398-404. 10.1590/S1020-49892009001100003, 20107690.
76. Jamison DT, Breman JG, Measham, et al. Disease Control Priorities in Developing Countries. 2006, New York: Oxford University Press, 2.
77. Jamison DT, Jamison JS. "Discounting". Disease Control Priorities Project Working Paper 4 2003, World Bank, Washington, DC.
78. Musgrove P. Public spending on health care: how are different criteria related?. Health Policy 1999, 47:207-23. 10.1016/S0168-8510(99)00024-X, 10538919.
79. Baltussen R, Asbroek AHA, Koolman X, Shrestha N, et al. Priority Setting using multiple criteria: should a lung health programme be implemented in Nepal?. Health Policy and Planning 2007, 22:178-185. 10.1093/heapol/czm010, 17412742.
80. Shillcutt SD, Walker DG, Goodman CA, et al. Cost effectiveness in low- and middle- income countries: a review of the debates surrounding decision rules. Pharmacoeconomics 2009, 27(11):903-17. 10.2165/10899580-000000000-00000, 2810517, 19888791.
81. Epstein DM, Chalabi Z, Claxton K, et al. Efficiency, equity, and budgetary policies: informing decisions using mathematical programming. Medical Decision Making 2007, 27:128-37. 10.1177/0272989X06297396, 17409363.
82. Baltussen R. Priority setting of public spending in developing countries: do not try to do everything for everybody. Health Policy 2006, 78:149-56. 10.1016/j.healthpol.2005.10.006, 16303204.